14 Stocks With Heavy Insider Buying In 2024
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets...
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
8.83 | |
8.88 | |
- | |
9.265 | |
8.75 | |
3.72-19.298 | |
288 M | |
32 590 K | |
0 | |
-0.87 | |
1.706 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets...
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: